目次

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
Diurnal Group Plc
Recordati SpA
Strongbridge Biopharma plc
Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing’s syndrome - Drug Profile
Product Description
Mechanism Of Action
CRN-04894 - Drug Profile
Product Description
Mechanism Of Action
osilodrostat phosphate - Drug Profile
Product Description
Mechanism Of Action
seliciclib - Drug Profile
Product Description
Mechanism Of Action
Silibinin - Drug Profile
Product Description
Mechanism Of Action
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2022: Recordati Rare Diseases announces publication of long-term outcomes from the extension to the phase III linc 3 Study of Isturisa(Osilodrostat) in patients with Cushing's Disease in the European Journal Of Endocrinology
Feb 04, 2021: Crinetics Pharmaceuticals lead ACTH antagonist for congenital adrenal hyperplasia and Cushing’s disease (CRN04894) advances into phase 1 study
Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Recordati SpA, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, 2022
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022